{"id":3014,"date":"2026-02-07T11:00:10","date_gmt":"2026-02-07T11:00:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/3014\/"},"modified":"2026-02-07T11:00:10","modified_gmt":"2026-02-07T11:00:10","slug":"it-seems-eli-lillys-eating-their-lunch-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/3014\/","title":{"rendered":"\u201cIt Seems Eli Lilly\u2019s Eating Their Lunch\u201d"},"content":{"rendered":"\n<p class=\"yf-vbsvxt\">Novo Nordisk A\/S (NYSE:<a href=\"https:\/\/finance.yahoo.com\/quote\/NVO\" data-ylk=\"slk:NVO;elm:context_link;itc:0;sec:content-canvas\" class=\"link \" rel=\"nofollow noopener\" target=\"_blank\">NVO<\/a>) is one of the <a href=\"https:\/\/www.insidermonkey.com\/blog\/jim-cramer-commented-on-these-14-stocks-1689624\/\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:stocks Jim Cramer commented on;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">stocks Jim Cramer commented on<\/a>. Cramer highlighted the company\u2019s post-earnings decline, as he remarked:<\/p>\n<p class=\"yf-1lvgyjz\">What went wrong at Novo Nordisk? Yesterday, the Danish drug maker behind Ozempic reported, and the stock plunged nearly 15% before sinking another 6% today. While the quarter was fine, the guidance, let\u2019s just say it was brutal. They\u2019re talking about a 5% to 13% sales hit this year, thanks to pricing pressures amid fierce competition for the GLP-1 business. It seems Eli Lilly\u2019s eating their lunch, even if it is a lunch that has no taste, an inevitable result of all GLPs.<\/p>\n<p>     <img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/92264ef32b70332cc4ea9283d978e1a6.jpeg\" alt=\"\" loading=\"eager\" height=\"640\" width=\"960\" class=\"yf-lglytj  loaded\"\/>     <\/p>\n<p class=\"yf-vbsvxt\">Stock market reports printed on a sheet of paper. Photo by RDNE Stock Project on Pexels<\/p>\n<p class=\"yf-vbsvxt\">Novo Nordisk A\/S (NYSE:NVO) manufactures pharmaceuticals for chronic conditions, including diabetes, obesity, and rare blood or endocrine disorders. The company also produces some medical devices. Cramer shared his thoughts on the stock when a caller inquired about it during the January 29 episode. The Mad Money host commented:<\/p>\n<p class=\"yf-1lvgyjz\">I kind of liked it when I spoke to them. I gotta tell you, I kind of warmed up\u2026 I was in San Francisco, and I said, you know what? I get that stock a little down more\u2026 But I love Eli Lilly and David Ricks, and what can I say? You know, as long as Eli Lilly and David Ricks are putting up those numbers and they get that pill form soon, I think that Novo is a hold, not a buy.<\/p>\n<p class=\"yf-vbsvxt\">While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you&#8217;re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the<a href=\"https:\/\/www.insidermonkey.com\/blog\/three-megatrends-one-overlooked-stock-massive-upside-1548959\/\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:best short-term AI stock;elm:context_link;itc:0;sec:content-canvas\" class=\"link \"> best short-term AI stock<\/a>.<\/p>\n<p class=\"yf-vbsvxt\">READ NEXT: <a href=\"https:\/\/www.insidermonkey.com\/blog\/30-stocks-that-should-double-in-3-years-1518528\/\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:30 Stocks That Should Double in 3 Years;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">30 Stocks That Should Double in 3 Years<\/a> and <a href=\"https:\/\/www.insidermonkey.com\/blog\/11-hidden-ai-stocks-to-buy-right-now-1523411\/\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:11 Hidden AI Stocks to Buy Right Now;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">11 Hidden AI Stocks to Buy Right Now<\/a>.<\/p>\n<p class=\"yf-vbsvxt\">Disclosure: None. This article is originally published at <a href=\"https:\/\/www.insidermonkey.com\/\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Insider Monkey;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Insider Monkey<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Cramer highlighted the company\u2019s post-earnings&hellip;\n","protected":false},"author":2,"featured_media":3015,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[3265,276,2961,272],"class_list":{"0":"post-3014","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-david-ricks","9":"tag-eli-lilly","10":"tag-jim-cramer","11":"tag-novo-nordisk"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/3014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=3014"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/3014\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/3015"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=3014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=3014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=3014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}